Issue 6/2014
Content (23 Articles)
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
Xavier García del Muro, Enrique Gallardo, Iciar García Carbonero, Nuria Laínez, María José Méndez, Pablo Maroto, María Ochoa de Olza, Javier Puente, Gaspar Reynes, José Rubio, Carmen Santander, Cristina Suárez, Sergio Vázquez Estévez, Daniel Castellano
Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
Robert C. Shumaker, Meijian Zhou, Min Ren, Jean Fan, Gresel Martinez, Jagadeesh Aluri, Borje Darpo
An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
Mona Darwish, John M. Burke, Edward Hellriegel, Philmore Robertson Jr., Luann Phillips, Elizabeth Ludwig, Mihaela C. Munteanu, Mary Bond
Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails
Weiheng Hu, Jian Fang, Jun Nie, Ling Dai, Xiaoling Chen, Jie Zhang, Xiangjuan Ma, Guangming Tian, Jindi Han
Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)
Joel M. Reid, Sarah A. Buhrow, Judith A. Gilbert, Lee Jia, Mamoru Shoji, James P. Snyder, Matthew M. Ames
Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy
Takahide Taguchi, Goshi Nishimura, Masahiro Takahashi, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Ken-ichiro Yabuki, Yasuhiro Arai, Hideaki Takahashi, Masaharu Hata, Izumi Koike, Nobuhiko Oridate
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis
Yan Wang, Yi-yi Yu, Wei Li, Yi Feng, Jun Hou, Yuan Ji, Yi-hong Sun, Kun-tang Shen, Zhen-bin Shen, Xin-yu Qin, Tian-shu Liu
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
Faruk Tas, Senem Karabulut, Rumeysa Ciftci, Fatma Sen, Burak Sakar, Rian Disci, Derya Duranyildiz
Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors
Fangfang Lv, Junning Cao, Jian Zhang, Jun Qian, Wei Peng, Si Sun, Wenhua Li, Wen Zhang, Weijian Guo, Jin Li
Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy
Jessica Mwinyi, Kerstin Vokinger, Alexander Jetter, Urs Breitenstein, Christian Hiller, Gerd A. Kullak-Ublick, Andreas Trojan
Pharmacokinetics of pazopanib administered in combination with bevacizumab
Diane-Charlotte Imbs, Sylvie Négrier, Philippe Cassier, Antoine Hollebecque, Andrea Varga, Ellen Blanc, Thierry Lafont, Bernard Escudier, Jean-Charles Soria, David Pérol, Etienne Chatelut
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
Katherine M. Slusarz, Vanessa L. Merker, Alona Muzikansky, Sanjeev A. Francis, Scott R. Plotkin
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors
Ramon Salazar, Serafin Morales, Marta Gil-Martín, Elena Aguirre, Ana Oaknin, Margarita Garcia, Sophie Callies, Enaksha R. Wickremsinhe, Karim A. Benhadji, Antonio Llombart
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Moon Ki Choi, Jung Yong Hong, Wonjin Chang, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Su Jin Lee, Silvia Park, Man Pyo Chung, Jong-Mu Sun, Keunchil Park, Myung-Ju Ahn, Jin Seok Ahn
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
Vassiliki Saloura, Ezra E. W. Cohen, Lisa Licitra, Salem Billan, Jose Dinis, Steen Lisby, Thomas C. Gauler
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard, Gedske Daugaard, Jean-Pascal Machiels, William Conkright, Sunil Sharma, Patricia M. M. B. Soetekouw, Jeffrey Yachnin, Lisa Sengeløv, Peter Van Veldhuizen, Sanjiv S. Agarwala, Dorothée Sémiond, Mustapha Chadjaa, Liji Shen, James L. Wade
Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial
Takashi Tsuchiya, Sotaro Sadahiro, Kazuaki Sasaki, Ken Kondo, Kenji Katsumata, Genichi Nishimura, Yoshihiro Kakeji, Hideo Baba, Takayuki Morita, Keiji Koda, Seiji Sato, Junji Matsuoka, Yoshiyuki Yamaguchi, Hisashi Usuki, Chikuma Hamada, Susumu Kodaira, Shigetoyo Saji
Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells
Sudipa S. Roy, Nameer B. Kirma, Bindu Santhamma, Rajeshwar R. Tekmal, Joseph K. Agyin
The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells
Kaamar Azijli, Ingrid A. M. van Roosmalen, Jorn Smit, Saravanan Pillai, Masakazu Fukushima, Steven de Jong, Godefridus J. Peters, Irene V. Bijnsdorp, Frank A. E. Kruyt
Pharmacokinetics and exposure–effect relationships of capecitabine in elderly patients with breast or colorectal cancer
Z. Daher Abdi, S. Lavau-Denes, A. Prémaud, S. Urien, F. L. Sauvage, J. Martin, S. Leobon, P. Marquet, N. Tubiana-Mathieu, A. Rousseau
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
Masanori Toyoda, Tetsuo Ajiki, Yutaka Fujiwara, Hiroaki Nagano, Shogo Kobayashi, Daisuke Sakai, Etsuro Hatano, Masashi Kanai, Shoji Nakamori, Atsushi Miyamoto, Akihito Tsuji, Satoshi Kaihara, Hisashi Ikoma, Shigekazu Takemura, Hideyoshi Toyokawa, Hiroaki Terajima, Satoshi Morita, Tatsuya Ioka
Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction
L. L. Krens, J. M. Baas, M. C. Verboom, G. Paintaud, C. Desvignes, H. J. Guchelaar, H. Gelderblom
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase
C. A. Fernandez, E. Stewart, J. C. Panetta, M. R. Wilkinson, A. R. Morrison, F. D. Finkelman, J. T. Sandlund, C. H. Pui, S. Jeha, M. V. Relling, P. K. Campbell